The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy

Sean Matthews, Antonio De Maria, Marco Passamonti, Giovanni Ristori, Idalba Loiacono, Anna Puggina, Desmond Curran, Sean Matthews, Antonio De Maria, Marco Passamonti, Giovanni Ristori, Idalba Loiacono, Anna Puggina, Desmond Curran

Abstract

Background: To estimate the health care resource utilization, costs, and impact on quality of life (QoL) of herpes zoster (HZ) and postherpetic neuralgia (PHN) in adults aged ≥50 years in Italy.

Methods: This was a prospective, observational, multicenter, community physician-based surveillance study (NCT01772160) in Italy. Health-related QoL data were collected using the EuroQoL-5 Dimension (EQ-5D) and Zoster Brief Pain Inventory (ZBPI) questionnaires. Both questionnaires were assessed at days 0 (HZ rash onset), 15, 30, 60, and 90 for all patients, and monthly thereafter for patients who developed PHN. Resource utilization was recorded for 3 months post-HZ onset and 9 months for PHN patients. Costs from both payer and societal perspectives were estimated and were composed of direct medical costs (general practitioner/specialist visits, procedures, hospitalizations, medications), work loss by patient/caregiver, and transport costs.

Results: A total of 391 patients with HZ were included, of whom 40 developed PHN. The mean ZBPI worst pain score was 5.7 at day 0, reducing to 2.6 at day 30 and 0.7 by day 90. Patients with PHN had a mean worst pain score of 5.7 at day 90. We estimated an overall disutility associated with HZ of 0.134. The mean cost per HZ patient from a payer/societal perspective was €153/€298, respectively, and the mean cost per HZ patients who developed PHN was €176/€426, respectively.

Conclusions: HZ is associated with impaired QoL and substantial health care resource use, highlighting the need for preventive strategies. This could reduce the disease burden for the patient and health care system.

Clinicaltrialsgov study registry: NCT01772160.

Keywords: QALY; economic burden; herpes zoster (HZ); postherpetic neuralgia (PHN); quality of life (QoL).

Figures

Figure 1.
Figure 1.
Mean Zoster Brief Pain Inventory worst pain scores by age category and time. Abbreviations: YOA, years of age; ZBPI, Zoster Brief Pain Inventory.
Figure 2.
Figure 2.
Mean costs by payer perspective and complication category. Abbreviations: HZ, herpes zoster; PHN, postherpetic neuralgia.
Figure 3.
Figure 3.
Focus on the patient.

References

    1. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999; 3:335–42.
    1. Brisson M, Edmunds WJ, Law B, et al. . Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127:305–14.
    1. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19:3076–90.
    1. Cohen JI. Herpes zoster. N Engl J Med 2013; 369:1766–7.
    1. Bricout H, Perinetti E, Marchettini P, et al. . Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009-2010): a GP-based prospective cohort study. BMC Infect Dis 2014; 14:1–11.
    1. Di Legami V, Gianino MM, Ciofi degli Atti M, et al. ; Zoster Study Group Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine 2007; 25:7598–604.
    1. Gialloreti LE, Merito M, Pezzotti P, et al. . Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 2010; 10:1–11.
    1. Levi M, Bellini I, Capecchi L, et al. . The burden of disease of herpes zoster in Tuscany. Hum Vaccin Immunother 2015; 11:185–91.
    1. Cocchio S, Baldovin T, Furlan P, et al. . Cross-sectional study on hospitalizations related to herpes zoster in an Italian region, 2008–2016. Aging Clin Exp Res. In press.
    1. Coplan PM, Schmader K, Nikas A, et al. . Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory. J Pain 2004; 5:344–56.
    1. EuroQol. Website of the EuroQol Group 2016. . Accessed 12 July 2016.
    1. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33:337–43.
    1. Scalone L, Cortesi PA, Ciampichini R, et al. . Italian population-based values of EQ-5D health states. Value Health 2013; 16:814–22.
    1. Coretti S, Codella P, Romano F, et al. . Cost-effectiveness analysis of herpes zoster vaccination in Italian elderly persons. Int J Technol Assess Health Care 2016; 32:233–40.
    1. Panatto D, Bragazzi NL, Rizzitelli E, et al. . Evaluation of the economic burden of herpes zoster (HZ) infection. Hum Vaccin Immunother 2015; 11:245–62.
    1. Arpinelli F, Bonzanini AC, Visonà G. La gestione clinica ed i costi dell’Herpes Zoster in Italia. G Farmacoeconomia 2000; 3:98–103.
    1. Scott FT, Johnson RW, Leedham-Green M, et al. . The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24:1308–14.
    1. Nakamura H, Mizukami A, Adachi K, et al. . Economic burden of herpes zoster and post-herpetic neuralgia in adults 60 years of age or older: results from a prospective, physician practice-based cohort study in Kushiro, Japan. Drugs Real World Outcomes 2017; 4:187–98.
    1. Schmidt-Ott R, Schutter U, Simon J, et al. . Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: a prospective study. J Infect 2018; 76:475–82.
    1. Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology 2013; 81:928–30.
    1. Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013; 13:1–10.
    1. United Nations Population Division. World population prospects: the 2006 revision population database.. Accessed 18 November 2017.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する